Protocol Ledger

NCT04405739 · Phase II · COMPLETED

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

Interventional Phase II clinical trial protocol NCT04405739 sponsored by Ridgeback Biotherapeutics, LP in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-16 Enrollment: 71 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04405739
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)71 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04405739
Protocol FieldVerified Registry Value
NCT IdentifierNCT04405739
Consolidated Lead SponsorRidgeback Biotherapeutics, LP
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment71 participants (ACTUAL)
Registered Start Date2020-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI